Nano-X Imaging (NNOX) Q2 2026 Earnings Call Transcript

Nano-X Imaging reported Q2 2026 revenue of $4.2 million, up 37% year over year, but recorded a $55.5 million GAAP net loss after a $40.7 million impairment of AI-related intangibles; adjusted EBITDA loss widened to $11.3 million. Cash and restricted deposits fell to $31.4 million from $60.0 million at year-end, and management disclosed substantial doubt about the company’s ability to continue as a going concern despite raising $8.5 million after quarter-end. Nanox is cutting headcount by 15% in Israel and 67% in South Korea, idling internal chip production and targeting $2 million of annual savings from 2027 while shifting manufacturing to third parties.

Analysis

NNOX's central issue is not demand generation but conversion: site-level permitting and buildout make its revenue recognition cycle structurally slower and less controllable than management's distributor-count narrative implies. The outsourced-production pivot removes fixed cost but also trades manufacturing control for supplier qualification, yield, and gross-margin risk; the modest targeted savings do not materially alter a loss structure that still requires external financing. The impairment is economically important because it resets the evidentiary burden for AI monetization and makes further acquisition-led revenue growth less credible without positive unit economics.

Near term, equity financing remains the dominant valuation variable. With cash burn running far above recurring revenue and an explicit going-concern disclosure, the post-quarter raise appears bridge capital rather than a funding solution; continued ATM issuance can create persistent share-price pressure irrespective of installation headlines. A meaningful rerating over the next 1-3 months requires audited evidence that active sites—not signed partners or pilots—are producing repeatable revenue and improving gross margin; otherwise, another capital raise is the base case.

RDNT is a second-order beneficiary: it can use a limited deployment to evaluate low-cost tomography while retaining purchasing leverage versus incumbent equipment vendors. VREX has asymmetric upside from third-party component adoption and broader emitter-testing optionality, but the addressable revenue is too immaterial today to change its earnings case. The contrarian upside in NNOX is that reimbursement attached to analysis of existing CT scans could scale faster than hardware deployment; however, reimbursement eligibility does not establish provider adoption, payer payment consistency, or sales conversion.

Key Decisions for Investors

• Maintain a short bias in NNOX over the next 3-6 months; use any installation-, reimbursement-, or RSNA-driven rally to establish/add, with a 20-25% hard stop. The thesis is dilution and weak conversion economics, not the non-cash impairment; cover if quarterly cash burn falls below $7 million while imaging/OEM revenue exceeds $1 million for two consecutive quarters.
• Do not underwrite NNOX on projected per-site economics until the company discloses active-site count, scans per site per month, net collections, and contribution margin. Set an alert for the next filing: another equity raise before demonstrated deployment productivity would reinforce the short thesis.
• For healthcare-imaging exposure, prefer a small long RDNT position versus NNOX rather than directional NNOX long exposure over 6-18 months. RDNT has the optionality to adopt lower-cost technology without bearing manufacturer funding and deployment risk; reassess if its clinical workflow evaluation expands into a material equipment rollout.
• Keep VREX on watch rather than initiate solely on this development. Upgrade only if VREX identifies a commercial program, volume commitments, or revenue contribution from the relationship; prototype and initial-testing language is not sufficient to model earnings.